RIL
CHRS icon

Rothschild Investment LLC’s Coherus Oncology CHRS Stock Holding History

Rothschild Investment LLC’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318 Buy
188
+129
+219% +$229 ﹤0.01% 3221
2025
Q4 		$84 Buy
+59
New +$86 ﹤0.01% 3225
2024
Q4 		– Sell
-95
Closed -$99 – 2975
2024
Q3 		$99 Buy
95
+30
+46% +$41 ﹤0.01% 2849
2024
Q2 		$112 Buy
+65
New +$131 ﹤0.01% 2704

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Rothschild Investment LLC's CHRS Position: Q1 2026 in Review

Rothschild Investment LLC increased its Coherus Oncology (CHRS) stake by 219% in Q1 2026, buying an estimated $229 and bringing the position to 188 shares worth $318. The position accounts for ﹤0.01% of the portfolio, ranked #3221.

Rothschild Investment LLC first reported a position in CHRS in Q2 2024 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Rothschild Investment LLC held 188 shares of Coherus Oncology worth $318 as of Q1 2026.
  • Rothschild Investment LLC bought 129 Coherus Oncology shares in Q1 2026, an estimated $229.
  • Coherus Oncology made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3221 holding.
  • Rothschild Investment LLC first reported a position in Coherus Oncology in Q2 2024 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.